Adagene Inc. ADAG
2.21 USD +0.08 (+3.52%)
Nov 12, 2026, 9:34 AM EST
2.07 Day range 2.28
1.50 52-week range 4.85
- YTD
- +16.67%
- 1 year
- +24.58%
News
benzinga.com Adagene Announces Completion Of Patient Enrollment In Its Phase 2 Study Of Muzastotug To Treat Microsatellite Stable Colorectal Cancer Without Liver Metastases Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced completion of…
globenewswire.com Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial - Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO…
benzinga.com Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
benzinga.com China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary…
benzinga.com Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that…- benzinga.com Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9 Chardan Capital analyst Gautam Chukka initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
benzinga.com Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.10) by 100 percent. This is a 5.26 percent decrease over losses of $(0.19) per…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026 Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Guggenheim Maintains Buy on Adagene, Raises Price Target to $10 Guggenheim analyst Paul Jeng maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price target from $9 to $10.
- benzinga.com Adagene Announces Results From Latest Data Cut From Phase 1b/2 Study Of Muzastotug In Patients With Advanced Microsatellite Stable Colorectal Cancer With No Liver Metastases Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement…
benzinga.com Adagene Collaborates With Incyte To Evaluate Combination Of Muzastotug And INCA33890 In Patients With Microsatellite Stable Colorectal Cancer With Or Without Liver Metastases Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastasesStudy will be sponsored and conducted by Incyte; Adagene to provide…- benzinga.com Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 52.94 percent increase over losses of $(0.51) per…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Adagene Announces Data Update From Ongoing Phase 1b/2 Study Of Muzastotug + Pembrolizumab In 3L+ MSS CRC Patients Remains On Track For Q1 2026 Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash and cash equivalents of $74.5 million as of December 31,…- benzinga.com Guggenheim Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9 Guggenheim analyst Paul Jeng initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Adagene Says First Patient Dosed In Randomized, Open Label Phase 2 Study Of Muzastotug In Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA In Patients With MSS CRC With No Liver Metastases Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDAPatients randomized to either 10 or 20 mg/kg of muzastotug,…- benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9 LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Adagene, Lowers Price Target to $7 HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and lowers the price target from $8 to $7.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Adagene H1 Adj. EPS $(0.19) Beats $(0.34) Estimate Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 26.92 percent increase over losses of $(0.26) per…
benzinga.com This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Leerink Partners Initiates Coverage On Adagene with Outperform Rating, Announces Price Target of $7 Leerink Partners analyst Daina Graybosch initiates coverage on Adagene (NASDAQ:ADAG) with a Outperform rating and announces Price Target of $7.
- benzinga.com Sanofi Invests Up to $25M in Adagene to Advance Cancer Drug Trials Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $8 Price Target HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $8 price target.
- benzinga.com Adagene Announces Investigator Initiated Phase 2 Trial For Neoadjuvant Muzastotug In Colorectal Cancer - Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major pathological response -SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE…
- benzinga.com HC Wainwright & Co. Maintains Buy on Adagene, Raises Price Target to $8 HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price target from $5 to $8.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.
- benzinga.com Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
- benzinga.com Adagene Announced New ADG126 Clinical Data From From Ongoing Phase 1b/2 Trial Of SAFEbody Plus Keytruda Combo
Presented At The ESMO Congress Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every…
- benzinga.com Adagene Presents New Phase 1b/2 Data on ADG126 and KEYTRUDA Combination Therapy for Metastatic CRC at ESMO Congress Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced new ADG126 clinical data presented at the ESMO…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Adagene Announced Progress, Expansion Of The Clinical Collaboration Development Program For Its Masked, Anti-CTLA-4 SAFEbody, ADG126 In Combination With Merck's Keytruda (Pembrolizumab), In Patients With Metastatic Microsatellite-stable Colorectal Cancer Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference - Initiated evaluation of 20…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com How Is The Market Feeling About Adagene?
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module.…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Why Is Cancer Focused Adagene Stock Plummeting Today? Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate…